[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)

Announced Date: 2023-10-12 (October 12, 2023)

Asset Name: YL202 (BNT326)

Licensor (Seller): MediLink Therapeutics (China)

Licensee (Buyer): BioNTech

.

Asset Modality: ADC (antibody drug conjugate) 

Asset Target: Human Epidermal Growth Factor Receptor 3 (HER3)

Potential Indication: Various cancer types, such as non-small cell lung cancer and breast cancer 

Stage until the Deal:  Phase 1

.

Scope of Authority:

MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets excluding Mainland China, Hong Kong and Macau.

.

Payment Detail:

Upfront payment totaling of $70 million,

Development, regulatory and commercial milestone payments potentially totaling over $1 billion.

.

Link:

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

Medilink Therapeutics

.

Note:

Chinese Name of “MediLink Therapeutics“，宜联生物